Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBIT (2016 - 2025)

Avalo Therapeutics' EBIT history spans 12 years, with the latest figure at -$19.7 million for Q4 2025.

  • For Q4 2025, EBIT fell 48.31% year-over-year to -$19.7 million; the TTM value through Dec 2025 reached -$72.9 million, down 6.44%, while the annual FY2025 figure was -$72.9 million, 6.44% down from the prior year.
  • EBIT reached -$19.7 million in Q4 2025 per AVTX's latest filing, down from -$19.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $4.1 million in Q3 2022 to a low of -$32.8 million in Q1 2024.
  • Average EBIT over 5 years is -$14.4 million, with a median of -$14.0 million recorded in 2024.
  • Peak YoY movement for EBIT: skyrocketed 124.87% in 2022, then crashed 272.69% in 2024.
  • A 5-year view of EBIT shows it stood at -$18.0 million in 2021, then soared by 50.7% to -$8.9 million in 2022, then grew by 13.52% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then tumbled by 48.31% to -$19.7 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's EBIT are -$19.7 million (Q4 2025), -$19.2 million (Q3 2025), and -$19.3 million (Q2 2025).